Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs
The Biden administration is looking to expand access to anti-obesity GLP-1 drugs like Ozempic and Wegovy for people who have Medicare and Medicaid.
Biden wants Medicare, Medicaid to cover pricey weight loss drugs such as Wegovy
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
Medicare May Soon Cover Ozempic, Wegovy Under New Biden Proposal
If the proposal is finalized, it could set the stage for a showdown between the pharmaceutical industry and the Trump administration.
Biden Will Move to Have Medicare, Medicaid Cover GLP-1 Weight-Loss Meds
The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid. However, the move would have to be approved by the new Trump administration.
Biden Proposal to Cover Obesity Drugs Sets Up Quandary for Trump
The Biden administration is proposing a rule that would require the US government to cover obesity drugs for millions of Americans, teeing up a financial and political challenge for President-elect Donald Trump as he prepares to take office.
Biden proposes expanded coverage for weight loss drugs under Medicare, Medicaid
The Biden administration has proposed a plan for Medicare and Medicaid to offer coverage for weight loss medications, such as Ozempic and Wegovy.
Biden Proposes Expanded Medicare, Medicaid Coverage of Obesity Drugs
Current rules for the Medicare and Medicaid government health insurance programs cover the use of drugs such as Mounjaro, Ozempic and Wegovy for certain conditions like diabetes, but not for obesity as a condition on its own.
GLP-1 weight-loss drugs might help protect kidneys
The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield ...
Millions more Americans might get access to GLP-1 drugs
Related: Crazy-expensive weight loss drugs may soon see a major change In other news, The Biden Administration is set to ...
As many as 1 in 5 people won't lose weight with GLP-1 drugs, experts say
About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to ...
Medscape3h
GLP-1 Labels Don’t Reflect Trial Exclusions
Clinicians are advised to screen patients for conditions that would have rendered them ineligible to participate in the ...
STAT1d
Inside the telehealth-fueled GLP-1 alternative market
The new class of GLP-1 weight loss drugs have been blockbusters since they arrived on the market a few years ago. These ...
West Virginia residents struggle to afford GLP-1 weight loss drugs after state ends subsidy program
In 2020, West Virginia launched a pilot program to subsidize GLP-1 drugs for public employees, but the program was shuttered ...
5 GLP-1 marketing trends as brands jump on weight loss drug craze
As use of GLP-1 weight loss drugs including Wegovy and Ozempic increases, brands are introducing new offerings.
Opinion
Employee Benefit News2hOpinion
Why GLP-1 patients need access to behavioral health support
Obesity is associated with increased odds of mood and anxiety disorders, including more serious mental health conditions such as schizophrenia and bipolar disease.
This new supplement aims to support natural GLP-1 production and gut health
Inno Supps’ Trim Biome™ GLP-1 is designed to support the body’s natural production of GLP-1 through a unique blend of ...
MedPage Today1d
Are GLP-1 Drugs Putting an End to Bariatric Surgery?
We go into depth, covering what bariatric surgery is, who needs it, why insurance makes it so hard to get it, and, most ...
Lexaria Bioscience’s Promising Outlook on GLP-1 Drugs
Lexaria Bioscience (LEXX) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now ...
Wait for longer-term data with Amgen's GLP-1, says Piper Sandler's Christopher Raymond
Wait for longer-term data with Amgen's GLP-1, says Piper Sandler's Christopher Raymond ...